Lilly(US:LLY) CNBC Television·2025-08-26 14:19Company Performance & Leadership - Eli Lilly's stock was considered undervalued after a weight loss trial result on August 7, 2025 [1] - CEO David Ricks purchased 1,632 shares at $645 on August 12 [1] - David Ricks is highly regarded and a frequent guest [4] Clinical Trial Analysis - A new trial released on August 26 involved adults with obesity or overweight and type two diabetes [2] - Including people with diabetes makes weight loss more challenging, highlighting the significance of the trial results [3] - The trial's success, while notable, may not justify a valuation of 31, suggesting a more reasonable valuation of 80-90 [3][4] Market Sentiment & Stock Performance - Year-to-date, the stock has fluctuated, experiencing both a 20% increase and a 20% decrease [5] - The speaker believes "this is the real deal" [5]